Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
High-Dose Oral Erythromycin Decreased the Incidence of Parenteral Nutrition-Associated Cholestasis in Preterm Infants

PAK C. NG,* CHEUK H. LEE,* SAMUEL P. S. WONG,‡ HUGH S. LAM,* FLORA Y. B. LIU,* KING W. SO,* CHEUK Y. LEE,* and TAI F. FOK‡

*Department of Pediatrics and ‡Department of Statistics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

Background & Aims: Feeding intolerance because of functional gastrointestinal dysmotility and parenteral nutrition-associated cholestasis (PNAC) are common problems in preterm, very-low-birth-weight (VLBW) infants. This double-blind, randomized, placebo-controlled study aimed to assess the effectiveness of “high-dose” oral erythromycin as a prokinetic agent in decreasing the incidence of PNAC. Two secondary end points, including the time to achieve full enteral feeding and the duration of parenteral nutrition, were also evaluated. Methods: Infants consecutively admitted to the neonatal unit were randomized to receive erythromycin (12.5 mg/kg/dose every 6 hours for 14 days) or an equivalent volume of normal saline (placebo) if they attained less than half the total daily fluid intake (<75 mL/kg/day) as milk feeds on day 14 of life. Results: Of 182 VLBW infants enrolled, 91 received erythromycin. The incidence of PNAC was significantly lower in erythromycin-treated infants (18/91) compared with placebo infants (37/91; P = .003). Treated infants achieved full enteral nutrition significantly earlier (mean, 10.1; SE, 1.7 days; P < .001), and the duration of parenteral nutrition was also significantly decreased by 10 days (P < .001). Importantly, fewer infants receiving erythromycin had 2 or more episodes of sepsis (n = 4) compared with placebo patients (n = 13, P = .03). No serious adverse effect was associated with erythromycin treatment. Conclusions: High-dose oral erythromycin can be considered as a rescue measure for VLBW infants who fail to establish adequate enteral nutrition and in whom anatomically obstructive pathologies of the gastrointestinal tract have been excluded.

Milk intolerance associated with nonanatomically obstructive (ie, functional) gastrointestinal dysmotility is a common feeding problem in preterm, very-low-birth-weight (VLBW; <1500 g) infants.1,2 This clinical entity is believed to be the consequence of ineffective, infrequent, and uncoordinated bowel activity secondary to immaturity of the gastrointestinal tract.1,2 The difficulty of accurate interpretation of clinical signs and symptoms related to feed intolerance and the constant fear of necrotizing enterocolitis (NEC)3,4 and gastrointestinal perforation associated with commonly used drugs such as corticosteroids and prostaglandin inhibitors5–7 often result in unnecessary and prolonged usage of parenteral nutrition. Because long-term hyperalimentation has been associated with increased risks of morbidity and life-threatening complications such as parenteral nutrition-associated cholestasis (PNAC),1,2 recurrent sepsis,8,9 biochemical rickets, nutritional deficiency and pain, as well as anesthetic risk because of repeated intravenous and long line insertion,10 prokinetic agents that can enhance gastrointestinal motility may be beneficial to these infants by promoting enteral feeding and reducing the duration of parenteral nutrition and associated adverse effects.

In 1997, we reported on a series of 7 preterm infants successfully treated with oral erythromycin for refractory gastrointestinal dysmotility.10 This affirmative experience led us to perform a preliminary randomized controlled trial (RCT) that demonstrated that oral erythromycin introduced at day 15 of life was effective in facilitating enteral feeding in VLBW infants with moderately severe gastrointestinal dysmotility.11 More importantly, there was a nonsignificant trend suggesting that more infants with prolonged feed intolerance developed PNAC in the placebo group than in the oral erythromycin group.11 However, there has been much controversy concerning the use of oral/intravenous erythromycin in promoting enteral feeding in preterm infants. To date, only a limited number of relatively small RCTs have been performed.11–18 Additionally, we considered that shortening of duration for achieving full enteral feeding alone was not a sufficient reason to recommend the use of prokinetic treatment in VLBW infants. Without definitive improvement in associated clinical outcomes such as PNAC, sepsis, and complications secondary to prolonged use of parenteral nutrition, treatment with erythromycin is

Abbreviations used in this paper: HIDA, hepatobiliary iminodiacetic acid; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PNAC, parenteral nutrition-associated cholestasis; VLBW, very low birth weight.

© 2007 by the AGA Institute
0016-5085/07/$32.00
doi:10.1053/j.gastro.2007.03.043
probably not clinically justified. Thus far, none of the published reports,\textsuperscript{12–18} including our own preliminary trial,\textsuperscript{11} has adequate statistical power to address these critical issues. We, therefore, extended our original study to evaluate the impact of erythromycin on important clinical outcomes. The primary objective of this RCT is to evaluate whether the use of “high” (antimicrobial) dose oral erythromycin as a “rescue” treatment for gastrointestinal dysmotility is able to decrease the incidence of PNAC in VLBW infants. Furthermore, there are 2 secondary objectives: (1) first, to estimate more precisely the benefit of oral erythromycin as a prokinetic agent in promoting enteral feeding and (2), second, to determine whether the use of oral erythromycin can shorten the duration for requirement of parenteral nutrition. Acquiring such information will enable neonatal clinicians to define better the usefulness of oral erythromycin as a prokinetic agent in vulnerable infants. A reduction in the incidence of PNAC and the number of days on parenteral nutrition would greatly improve the well-being of preterm infants and could also translate into substantial savings on hyperalimentation and the need for investigation of prolonged cholestatic jaundice.

Materials and Methods

Patients

VLBW infants consecutively admitted to the neonatal intensive care unit (NICU) at the Prince of Wales Hospital, Hong Kong, during the 2 time periods—(1) November 1998 to May 2000 (phase 1) and (2) August 2002 to September 2006 (phase 2)—and satisfying the inclusion and exclusion criteria were eligible for recruitment into the study. The phase 1 study represented the period in which patients were recruited for the preliminary RCT,\textsuperscript{11} and the phase 2 study comprised the period of subsequent recruitment for the extended trial. The gap period of nonrecruitment was the time taken to plan the phase 2 study and to apply for external funding to continue with the research project. The inclusion and exclusion criteria for the 2 recruitment periods were identical. In brief, the inclusion criteria were preterm infants (1) with birth weight \(\geq 1500\) g, (2) who received less than half of the total daily fluid intake or \(<75\) mL/kg/day of milk feeds by the oral route on day 14 of postnatal age, and (3) with parental consent for entering into the study.\textsuperscript{11} Infants were excluded if they had the following: (1) lethal congenital abnormalities or chromosomal disorders; (2) congenital cyanotic heart disease; (3) anatomic obstructive gastrointestinal pathologies, such as intestinal malrotation with or without volvulus, stenosis, or atresia, gastrochisis, exomphalos and Hirschsprung’s disease; (4) NEC; or (5) undergone major gastrointestinal surgery within the first 14 days of life.\textsuperscript{11} The study was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong for both phase 1 and phase 2 studies, and written parental consent was obtained before randomization and enrolment for each case.

Sample Size

After the phase 1 study, we retrospectively reviewed the incidence of PNAC in VLBW infants in the NICU. Cholestatic jaundice is conventionally defined as serum conjugated bilirubin concentration \(>34\) mmol/L (ie, \(>2\) mg/dL) in newborns.\textsuperscript{2,19–21} Although the cut-off value is considered arbitrary and does not necessarily correlate with any specific hepatic pathology, it has been extensively used in neonatal studies.\textsuperscript{2,19–21} The incidence of PNAC in VLBW infants who failed to attain half the expected volume of enteral feeding on day 14 for the past 3 consecutive years was found to vary between 35% and 43%. We made the assumption of decreasing the incidence from 40% to 20% after introducing oral erythromycin, and it was determined that 91 infants would be required in each arm (ie, a total of 182 infants) of an RCT to detect a significant difference at the 5% level and with a power of 80%. Because our experience in the phase 1 study indicated that we could recruit 56 infants with gastrointestinal dysmotility within a period of 19 months, we expected to complete the recruitment of the extra 126 infants within a 43-month period. We managed to enroll the full quota of patients in 50 months (phase 2 study). The delay was most likely due to the substantial drop in admissions to the NICU at the Prince of Wales Hospital during the severe acute respiratory syndrome (SARS) outbreak in March 2003 in Hong Kong because we admitted 2 of the sickest preterm infants born to mothers with SARS-associated coronavirus infection.\textsuperscript{22} The NICU statistics suggested that the general public took at least 6 to 9 months to regain confidence to give birth at the Prince of Wales Hospital and, hence, could explain the slight delay of the recruitment process.

Randomization

VLBW infants satisfying the entry criteria were randomly assigned by a computer minimization program on day 14 to receive either oral erythromycin or the placebo solution (normal saline). A research assistant not involved in the clinical care of infants performed the randomization by minimizing 3 predetermined clinical parameters that could potentially influence enteral feeding: gestational age, birth weight, and age at introduction of enteral feeding.\textsuperscript{11} The attending clinical team looking after the infants was completely unaware of the randomization assignments because each recruited infant was labeled with a trial code number.

Medications

The enteral route of drug administration was purposefully chosen because life-threatening or fatal cardiac dysrhythmias associated with erythromycin were mainly
observed in patients with parenteral route of drug delivery. The peak serum erythromycin concentration after an intravenous infusion is typically 4- to 10-fold higher than the circulating level achieved by the same medication when it is given orally. Because the safe dosage of intravenous erythromycin has not been determined in VLBW infants, administration of this drug by the intravenous route is, therefore, best avoided.

Oral erythromycin was commenced on day 15 of life because of the following reasons. A recent, large, population-based study has indicated that, although early exposure to erythromycin (ie, 3–13 days of life) was associated with an 8-fold increased risk of developing infantile hypertrophic pyloric stenosis, there was no evidence to suggest any increase in risk exposing to the same medication after 13 days of postnatal age. Second, the timing and dosage of drug administration between the first and the second phase of the study should be the same. Third, we considered starting prokinetic treatment on day 15 of life to be optimal because oral erythromycin was used in this study as a “rescue” treatment. Thus, adequate time should be allowed for assessing the severity of gastrointestinal dysmotility and to exclude anatomic bowel obstruction, NEC, and other ominous gastrointestinal pathologies.

We opted to use a high (antimicrobial) dose of erythromycin (12.5 mg/kg/dose) in preference to a low-dose regime (1.5–5 mg/kg/dose) because of the following: (1) our previous clinical experience in the case series study and our preliminary RCT both suggested that the high-dose regime was effective in promoting milk feeding and significantly reduced the time to achieve full enteral nutrition in VLBW infants, (2) higher doses of erythromycin have been shown to shorten the whole gut transit time and facilitate gastric emptying by stimulating postprandial antroduodenal motor activity, and (3) previous studies using the low-dose regime often required large intravenous loading doses of erythromycin (15–30 mg/kg/day) for the first few days of treatment, and the oral route of drug administration is likely to be associated with a lower serum concentration than that achieved by the intravenous route.

Patients randomized to receive the active treatment were prescribed erythromycin (Ery-Ped, erythromycin ethylsuccinate diluted to 12.5 mg/mL with sterile water; Abbott Laboratories, Abbott Park, IL) 12.5 mg/kg given every 6 hours, whereas infants allocated to receive the placebo solution were given an equivalent volume of normal saline. Because the Ery-Ped is a white liquid suspension, both the active drug and placebo solution were mixed thoroughly into milk feeds to mask their appearance from the attending neonatal team. This task was performed by 2 designated research staff members who were not involved in the daily clinical care of these infants. Furthermore, the drug preparation was identified only by a trial code number to ensure effective blinding.

The drug treatment was started on day 15 of postnatal age immediately after randomization, and all infants received a 14-day course of treatment. If oral feeding had to be discontinued after starting the study, all oral medications, including erythromycin and placebo solution, were suspended. Administration of the study solutions was resumed only after the infants were restarted on enteral nutrition. During both phases of the study, the use of other prokinetic agents such as cisapride, domperidone, and metoclopramide was strictly prohibited. Electrocardiography was performed immediately before and in the second week of drug treatment to assess the QTc intervals.

**Enteral and Parenteral Nutrition**

All VLBW infants were routinely started on parenteral nutrition (6% TrophAmine; McGaw Inc, Irvine, CA, and 20% Intralipid; Kabi Pharmacia AB, Stockholm, Sweden) on day 3 of life according to the unit guidelines. Oral milk feeds were usually started within the first week of life (usually between day 3 and day 6) at the discretion of the attending clinical team and were given as intermittent boluses under gravity through the orogastric tube starting at 1 mL/h. The attending nurse aspirated the stomach once every 4 hours to measure the gastric residuals. Oral intake was then increased cautiously at a rate of 0.5–1 mL/h/day as tolerated. Infants were fed mother’s milk whenever possible, but preterm commercial formulas were also used with mothers’ permission if breast milk was not available. All infants were examined at least twice a day and closely monitored for the occurrence of regurgitation/vomiting, diarrhea, abdominal distention, and volume of gastric residuals. A strict protocol was implemented for discontinuing and restarting of enteral feeding. The attending clinician would consider discontinuing enteral feeding when (1) vomiting or significant regurgitation more than 2 times in 24 hours, (2) volume of gastric residuals exceeded half of the oral intake in the previous 4 hours on 2 occasions within the same day, (3) clinical signs and symptoms were suggestive of NEC or other sinister intraabdominal pathologies, and (4) repeated regurgitation resulting in aspiration pneumonia. Oral feeding together with the study drug was resumed as soon as the above signs and symptoms subsided. The end points of the study were defined as achieving 75, 115, and 150 mL/kg/day, respectively, of milk feeds.

**Investigation of PNAC**

All infants receiving parenteral nutrition had liver function monitored weekly until discharged from the NICU or when the parameters reverted back to the normal range. Because each of the enrolled infants were assigned a trial code number, both groups of patients were monitored identically. Infants suspected of PNAC and who had deranged hepatic function for more than 4
weeks or did not show any improvement after discontinue-
ation of parenteral nutrition were subjected to further
investigations. Paired serologic titers for hepatitis A, B,
and C; toxoplasmosis, rubella, cytomegalovirus, and her-
pes virus type 2 (TORCH); and syphilis were performed.
Urine samples were collected for cytomegalovirus shell
vial culture. These infants also had ultrasound assess-
ment of the liver and biliary structures after priming with
phenobarbitone, and those with suspicious or abnormal
scans were further subjected to the 99mTc hepatobiliary
iminodiacetic acid (HIDA) scan. If biliary atresia could
not be ruled out by radiologic tests, liver biopsy and/or
operative cholangiography were recommended. This al-
gorithm for investigation of neonatal liver disease and
prolonged conjugated hyperbilirubinemia was the guide-
line of the NICU and strictly enforced during the study
period.

Microbiologic Studies

Stool samples for microbiologic culture were col-
lected from the studied infants immediately before treat-
ment, after 10 days of medication, and 4 weeks after the
treatment had been terminated. All specimens were cul-
tured on a wide range of selective culture media as pre-
aviously described. In brief, these culture media included
the following: (1) deoxycholate citrate agar, thiosulphate
citrate bile sucrose agar, MacConkey agar and selenite-F
enrichment broth (further subcultured onto deoxy-
cholate citrate agar after incubation), incubated aerobi-
cally at 37°C for 18–24 hours; (2) blood agar supple-
mented with vitamin K1 and cycloserine cefoxitin
fructose agar incubated anaerobically at 37°C for 48
hours; (3) Skirrow agar incubated under microaerophilic
conditions at 42°C for 48 hours; and (4) Sabouraud
dextrose agar incubated aerobically at 30°C for 48 hours.
Stool pathogens, including Salmonella species, Shigella
species, thermophilic Campylobacter species, and Vibrio
species, were identified using standard biochemical test,
the API systems (bioMerieux, Marcy-I’ Etoile, France),
and serologic tests where appropriate. Predominant or
pure growth of aerobes, anaerobes, and fungi were re-
corded. The microbiologists who performed the stool
culture were unaware of the randomization assignments.
These microbiologic tests were, however, discontinued
after the outbreak of SARS in March 2003 because of the
heavy workload in the laboratory and restructuring of the
service. Thus, only the initial 41% of infants (37 and 38
infants in the erythromycin and placebo group, respec-
tively) had the microbiology tests performed to look for
any change in the pattern of bacterial colonization in the
bowel.

Data Collection

The demographic data and clinical characteristics
of infants are summarized in Table 1. Details of enteral
feeding, including the time after randomization achiev-

ing half, three-quarters, and full enteral feeding; types of
milk feeds; and duration of parenteral nutrition and
potential adverse effects, and complications associated
with the drug treatment and prolonged hyperalimenta-
tion, such as the incidence of infantile hypertrophic py-
loric stenosis, cardiac dysrhythmias, electrocardiographic
QTC intervals before and during oral erythromycin treat-
ment, and changes in stool microbial flora, were moni-
tored. Important clinical outcomes in addition to PNAC,
including sepsis, bronchopulmonary dysplasia, intraventric-
tricular hemorrhage, NEC, duration of hospitalization,
and mortality were also documented.

Statistical Analysis

The Fisher exact test and Mann–Whitney U test
were used to compare proportions and continuous vari-
ables between groups when appropriate. The mixed-ef-
fects models were used to assess the longitudinal data
on feeding after adjustment for individual random fac-
tors. All tests were performed by the Windows version of
S-Plus 2000 (MathSoft, Inc., Seattle, WA). The mixed-
effects models were fitted using the function lme in
S-Plus. All comparisons were 2-tailed, and the level of
significance was set at 5%. The results were analyzed on
an intention-to-treat basis.

Results

Ninety-five and 243 VLBW infants were admitted
to the NICU during phase 1 and phase 2, respectively, of
the study over a total period of 69 months, and of whom
56 and 126 infants with moderately severe gastrointesti-
nal dysmotility were enrolled, respectively. The schematic
flow chart revealed details of the recruitment process
(Figure 1). Ninety-one infants received oral erythromycin,
and an equal number received the placebo solution. The
clinical characteristics of the groups are summarized in
Table 1. All clinical features except the oxygenation index
at 12 hours of life were comparable between the 2 groups.
Erythromycin-treated infants had significantly higher ox-
egenation index than placebo infants in the immediate
perinatal period (P = .04; Table 1).

The clinical outcomes are summarized in Table 2. The
incidence of PNAC was significantly higher in the pla-
cebo (37/91 infants) than in the oral erythromycin group
(18/91 infants, P = .003). Investigations for cholestatic jaundice indicated that 1 infant in the placebo group was
infected with cytomegalovirus, and the infant had posi-
tive urinary excretion of the virus, and another infant in
the oral erythromycin group failed the 99mTc HIDA scan
and was suspected to have biliary atresia. The parents of
the latter infant refused operative cholangiography and
liver biopsy, but the patient recovered uneventfully after
achieving full enteral feeding and discontinuation of
parenteral nutrition. The inclusion or exclusion of these
2 cases did not significantly alter the overall outcome of
PNAC. Although the overall maximum serum total bili-
rubin and conjugated bilirubin concentrations did not differ significantly between groups, the maximum serum alanine aminotransferase concentration was significantly higher in infants receiving the placebo solution ($P = 0.04$; Table 2). Significantly more placebo infants (23/91 infants) had abnormally elevated serum alanine aminotransferase concentration (normal range, $53$ IU/L) compared with erythromycin-treated patients (11/91 infants; $P = 0.036$).

The mixed-effects models were used to analyze the longitudinal data on feeding after adjustment for the first day of milk introduction. The results indicated that VLBW infants were able to achieve half, three-quarters, and full enteral nutrition (mean [SE]) 18.1 [0.8], 25.8 [1.0], and 33.7 [1.4] days, respectively, after introduction of milk feeding, but this process could be advanced by 5.1 [0.8], 7.6 [1.3], and 10.1 [1.7] days to 13.0 [0.5], 18.3 [0.7], and 23.6 [1.0] days, respectively, if oral erythromycin was used simultaneously ($P < 0.001$ in all comparisons). Furthermore, infants were able to achieve half, three-quarters, and full enteral feeding 9.5 [0.8], 17.2 [1.0], and 25.0 [1.4] days, respectively, after starting the placebo solution, and this duration could be shortened significantly to 4.1 [0.4], 9.3 [0.6], and 14.4 [0.9] days (ie, shortened by 5.3 [0.8], 8.0 [1.2], and 10.6 [1.6] days), respectively, by oral erythromycin treatment ($P < 0.001$ in all comparisons). Additionally, the median times of parenteral nutrition and lipid infusion in erythromycin-treated infants

### Table 1. The Clinical Characteristics of the Oral Erythromycin and Placebo Groups

| Clinical Characteristics                          | Oral erythromycin group (n = 91) | Placebo group (n = 91) | $P$ values |
|-------------------------------------------------|----------------------------------|------------------------|------------|
| Gestational age (wk)                            | 28.6 (27.3–30.5)                 | 28.9 (26.6–30.6)       | 0.96       |
| Birth weight (g)                                | 1095 (868–1285)                  | 1090 (890–1375)        | 0.91       |
| Sex                                             |                                   |                        |            |
| Female:Male, n                                   | 46 (51%):45 (49%)                | 47 (52%):44 (48%)      | 1.00       |
| Inborn infants, n                                | 90 (99%)                         | 89 (98%)               | 1.00       |
| Mode of delivery:                                |                                   |                        |            |
| Cesarean section:vaginal, n                      | 49 (54%):42 (46%)                | 47 (52%):44 (48%)      | 0.88       |
| Antenatal dexamethasone:                         |                                   |                        |            |
| Mothers received antenatal dexamethasone, n      | 74 (81%)                         | 76 (84%)               | 0.85       |
| Dosage (mg)                                      | 20 (6–24)                        | 20 (6–24)              | 0.77       |
| Time intervals between last dose of dexamethasone and delivery (h) | 26.5 (5.25–72.0) | 23.5 (6.0–72.0) | 0.93 |
| Apgar scores:                                    |                                   |                        |            |
| 1 Min                                           | 7 (5–8)                          | 7 (6–8)                | 0.46       |
| 5 Min                                           | 9 (7–10)                         | 8 (8–9)                | 0.35       |
| Arterial cord blood                              |                                   |                        |            |
| pH                                              | 7.29 (7.25–7.32)                 | 7.30 (7.22–7.34)       | 0.88       |
| Base excess (mmol/L)                             | −4.0 (−5.3 to −2.5)              | −4.1 (−7.0 to −2.0)    | 0.45       |
| First venous hematocrit after delivery           | 0.49 (0.44–0.54)                 | 0.49 (0.45–0.55)       | 0.48       |
| Temperature on admission (°C)                    | 36.2 (35.8–36.5)                 | 36.0 (35.8–36.5)       | 0.32       |
| Infants requiring exchange transfusion, n        | 3 (3%)                           | 2 (2%)                 | 1.0        |
| CRIB score                                       | 2 (1–4)                          | 2 (1–3)                | 0.70       |
| Oxygenation index (at 12 h)                      | 5.8 (3.3–13.2)                   | 4.3 (2.7–8.0)          | 0.04$^a$  |
| Patent ductus arteriosus, n                      | 38 (42%)                         | 31 (34%)               | 0.36       |
| Umbilical arterial catheter:                     |                                   |                        |            |
| Number of infants, n                             | 59 (65%)                         | 53 (58%)               | 0.45       |
| Duration (days)                                  | 8 (0–17)                         | 6 (0–15)               | 0.38       |
| Umbilical venous catheter:                       |                                   |                        |            |
| Number of infants                                | 79 (87%)                         | 78 (86%)               | 1.00       |
| Duration (days)                                  | 15 (8–23)                        | 14 (6–21)              | 0.38       |
| Type of milk feeds:                              |                                   |                        |            |
| Breast milk:formula milk:mixed, n                | 19 (21%):22 (24%):50 (55%)       | 13 (14%):21 (23%):57 (63%) | 0.45 |
| Postnatal drugs                                  |                                   |                        |            |
| Fentanyl:                                        |                                   |                        |            |
| Number of infants                                | 77 (85%)                         | 80 (88%)               | 0.67       |
| Duration (days)                                  | 5 (1–8)                          | 3 (2–14)               | 0.91       |
| Vecuronium:                                      |                                   |                        |            |
| Number of infants                                | 11 (12%)                         | 16 (18%)               | 0.40       |
| Duration (days)                                  | 0 (0–0)                          | 0 (0–0)                | 0.37       |
| Indomethacin:                                    |                                   |                        |            |
| Number of infants                                | 68 (75%)                         | 62 (68%)               | 0.41       |

Note. Results are expressed as median (interquartile range) and number (%).

CRIB. Clinical risk index for babies.

$^aP < .05$. 

*Table 1. The Clinical Characteristics of the Oral Erythromycin and Placebo Groups*
Figure 1. A schematic flow chart revealing details of the recruitment process in both phase 1 and phase 2 of the study.
were both significantly decreased by 10 days ($P < .001$; Table 2).

The number of infants with culture proven septicemia were similar between the oral erythromycin (n = 26) and the placebo group (n = 27; Table 3). Nine (10%) and 11 (12%) infants in the erythromycin and placebo group developed septicemia during the treatment period, respectively. However, significantly fewer infants receiving oral erythromycin had 2 or more episodes of septicemia (n = 4) compared with their placebo counterparts (n =

| Clinical outcomes                                      | Oral erythromycin group (n = 91) | Placebo groups (n = 91) | $P$ values |
|--------------------------------------------------------|----------------------------------|-------------------------|------------|
| **Gastrointestinal outcomes**                          |                                  |                         |            |
| Age commenced on enteral feeding (days)                | 6 (4–8)                          | 6 (4–8)                 | .65        |
| Age commenced on trial medications (days)              | 15 (14–16)                       | 15 (14–15)              | .12        |
| Time after birth achieved half enteral feeding (75 mL/kg/day) (days) | 18 (17–21)                       | 21 (18–28)              | <.001<sup>a</sup> |
| Time after birth achieved three-quarters enteral feeding (115 mL/kg/day) (days) | 22 (20–28)                       | 29 (23–38)              | <.001<sup>a</sup> |
| Time after birth achieved full enteral feeding (150 mL/kg/day) (days) | 26 (23–32)                       | 38 (30–50)              | <.001<sup>a</sup> |
| Duration of parenteral nutrition (days)                | 23 (19–30)                       | 33 (22–47)              | <.001<sup>a</sup> |
| Duration of lipid infusion (days)                      | 20 (16–26)                       | 30 (20–44)              | <.001<sup>a</sup> |
| Necrotizing enterocolitis (after day 14), n            | 0 (0%)                           | 1 (1%)                  | 1.00       |
| Infantile hypertrophic pyloric stenosis, n             | 0 (0%)                           | 0 (0%)                  | 1.00       |
| **Hepatic outcomes**                                   |                                  |                         |            |
| PNAC (conjugated hyperbilirubinemia >34 mmol/L), n     | 18 (20%)                         | 37 (41%)                | .003<sup>b</sup> |
| Maximum serum total bilirubin concentration (mmol/L)   | 169 (148–192)                    | 165 (151–188)           | .88        |
| Maximum serum conjugated bilirubin concentration (mmol/L) | 23 (15–31)                      | 27 (13–61)              | .08        |
| Maximum serum alanine aminotransferase concentration (IU/L) | 19 (13–30)                      | 27 (13–50)              | .04<sup>a</sup> |
| Infants with abnormal liver enzyme (serum alanine aminotransferase concentration >53 IU/L), n | 11                             | 23                      | .04<sup>a</sup> |
| **Cardiorespiratory outcomes**                         |                                  |                         |            |
| Duration of IPPV/HFOV (days)                           | 6 (4–14)                         | 5 (3–18)                | .48        |
| Duration of mechanical ventilation (days)              | 24 (11–47)                       | 24 (7–44)               | .34        |
| Maximum mean airway pressure (cm H2O)                  | 10.5 (8.0–13.0)                  | 9.8 (7.8–12.5)          | .31        |
| Maximum O2 concentration                               | 0.40 (0.30–0.59)                 | 0.35 (0.25–0.50)        | .15        |
| Duration of O2 dependence (days)                       | 15 (3–33)                        | 10 (1–30)               | .21        |
| O2 requirement >28 days, n                             | 31 (35%)                         | 26 (29%)                | .42        |
| O2 supplementation at 36 weeks postconceptual age, n  | 10 (11%)                         | 5 (5%)                  | .14        |
| O2 supplementation at 36 weeks postconceptual age plus death cases, n | 11 (12%)                      | 8 (9%)                  | .48        |
| QTc interval before medication (ms)                    | 0.38 (0.36–0.41)                 | 0.38 (0.35–0.40)        | .66        |
| QTc interval after medication (ms)                     | 0.39 (0.36–0.41)                 | 0.38 (0.36–0.41)        | .78        |
| Ventricular ectopics, n                               | 1                               | 2                       | 1.00       |
| **Microbiologic outcomes**                             |                                  |                         |            |
| Number of infants with septicemia, n<sup>c</sup>       |                                  |                         |            |
| 0 Episode                                              | 65 (71%)                         | 64 (70%)                | .42        |
| 1 Episode                                              | 22 (24%)                         | 14 (15%)                | .60        |
| 2 Episodes                                             | 2 (2.5%)                         | 11 (12.5%)              | .34        |
| 3 Episodes                                             | 2 (2.5%)                         | 2 (2.5%)                | .03<sup>b</sup> |
| Stool culture (gram-positive organism:gram-negative organism:fungus), n<sup>d</sup> | 13:7:2                         | 14:10:1                 | .73        |
| Immediately before drug treatment                      | 14:8:3                           | 13:14:2                 | .48        |
| During drug treatment                                  | 8:8:1                            | 8:11:2                  | .89        |
| 4 Weeks after termination of drug treatment            |                                  |                         |            |
| **Others**                                             |                                  |                         |            |
| Intraventricular hemorrhage, n                         |                                  |                         |            |
| Grade 0–2                                              | 85 (93%)                         | 82 (90%)                | .59        |
| Grade 3 or 4                                           | 6 (7%)                           | 9 (10%)                 | .59        |
| Duration of hospitalization (days)                     | 80 (66–104)                      | 88 (66–125)             | .20        |
| Died, n                                                | 2 (2%)                           | 4 (4%)                  | .95        |

NOTE. Results were median (interquartile range) and number (%).
HFOV, high frequency oscillatory ventilation; IPPV, intermittent positive pressure ventilation; PNAC, parenteral nutrition-associated cholestasis.

<sup>a</sup>$P < .001$.

<sup>b</sup>$P < .05$.

<sup>c</sup>The Fisher exact test was used to compare the number of episodes of septicemia between the erythromycin and placebo groups. There was a significant overall difference between groups ($P = .032$). Furthermore, if the number of episodes of septicemia was categorized into 0 or 1 episodes vs 2 or 3 episodes, the results remained significantly different between erythromycin-treated and nontreated infants ($P = .039$).

<sup>d</sup>Only the first 75 infants had samples sent for stool culture, of whom 37 infants received oral erythromycin and 38 infants received the placebo solution.
Furthermore, an overall analysis on the timing of septicemic episodes indicated that sepsis occurred significantly later in life in placebo infants (median, 24.5; interquartile range, 17.3–42.5 vs median, 34.0; interquartile range, 24.3–52.0 days for the erythromycin and placebo groups, respectively; \( P < 0.035 \)). The organisms causing septicemia are listed in Table 3, and the predominant growth of organisms from stool cultures immediately before, during, and 4 weeks after the drug treatment are summarized in Table 4. There was no evidence to suggest any outbreak of infection or emergence of multidrug-resistant organisms during the study period. Other important outcomes, including bronchopulmonary dysplasia defined as oxygen requirement >28 days or at 36 weeks postconceptional age (with or without including death cases), NEC, periventricular hemorrhage, duration of hospitalization, and number of death cases did not differ significantly between groups. There was also no significant increase in potential adverse effects associated with oral erythromycin treatment such as prolongation of QTc intervals, cardiac dysrhythmia, or emergence of a specific group of resistant organisms in the bowel flora. No cases of infantile hypertrophic pyloric stenosis were observed in either group.

### Discussion

This is the first RCT of erythromycin to address the issue of clinical outcomes in VLBW infants. Our findings suggested that the use of high-dose oral erythromycin as a rescue measure for gastrointestinal dysmotility in preterm VLBW infants could significantly reduce the incidence of PNAC. The time to reach full enteral feeding, the need for hyperalimentation, and the incidence of recurrent septicemia were also significantly decreased.

PNAC, defined as serum conjugated bilirubin concentration >34 mmol/L,\(^2,19–21\) is a common problem and is estimated to occur between 35% and 43% of VLBW infants with gastrointestinal dysmotility in our NICU. The prevalence in the current study was 41% and is within the range of our estimation. Our results suggested that the incidence of PNAC in the placebo group was doubled

### Table 3. Organisms Causing Septicemia

| Organisms                        | Oral erythromycin group | Placebo group |
|----------------------------------|-------------------------|---------------|
| Number of septicemic episodes, n | 32                      | 42            |
| Gram-positive organisms:         |                         |               |
| Coagulase-negative staphylococci | 21                      | 28            |
| *Enterococcus* species           | 1                       | 1             |
| *Staphylococcus aureus*          | 2                       | –             |
| Methicillin-resistant            | 1                       | 1             |
| *Staphylococcus aureus*          |                         |               |
| Gram-positive *Bacillus* species | 1                       | 4             |
| *Micrococcus* species            | –                       | 1             |
| Gram-negative organisms:         |                         |               |
| *Serratia* species               | 1                       | 3             |
| *Escherichia coli*               | 1                       | 1             |
| *Klebsiella* species             | 1                       | –             |
| *Acinetobacter* species          | 1                       | –             |
| *Pseudomonas* species            | –                       | 1             |
| Fungi:                           |                         |               |
| *Candida albicans*               | 1                       | 2             |
| *Candida parasilosis*            | 1                       | –             |

### Table 4. Predominant Growth of Organisms From Stool Cultures Immediately Before, During, and 4 Weeks After Oral Erythromycin and Placebo Treatment

| Organisms                        | Oral erythromycin group (n = 37) | Placebo group (n = 38) |
|----------------------------------|----------------------------------|------------------------|
| Number of positive stool cultures, n | 22                               | 25                     |
| Gram-positive organisms:         | 25                               | 20                     |
| 4 Weeks after treatment          | 17                               | 21                     |
| Immediately before treatment     |                                  |                        |
| During treatment                 |                                  |                        |
| 4 Weeks after treatment          |                                  |                        |
| Immediately before treatment     |                                  |                        |
| During treatment                 |                                  |                        |
| 4 Weeks after treatment          |                                  |                        |
| Coagulase-negative *staphylococci* | 9                                 | 10                     |
| *Nonhemolytic streptococci*      | 1                                 | –                      |
| *Staphylococcus aureus*          | 2                                 | 1                       |
| Methicillin-resistant *S. aureus* | –                                 | –                       |
| *Enterococcus* species           | 1                                 | 4                       |
| *Bacteroides fragilis*           | 1                                 | 1                       |
| *Pseudomonas* species            | 1                                 | 1                       |
| *Acinetobacter* species          | 1                                 | 1                       |
| *Stenotrophomonas* species       | 2                                 | 1                       |
| *Klebsiella* species             | 2                                 | 2                       |
| *Enterobacter* species           | 1                                 | 2                       |
| *Proteus* species                | 1                                 | 1                       |
| *Serratia* species               | 1                                 | 2                       |
| *Citrobacter* species            | –                                 | 2                       |
| Fungi:                           | *Candida* species                 | 2                       |

May 2007 ORAL ERYTHROMYCIN DECREASED CHOLESTASIS 1733
compared with infants treated with erythromycin. Thus, the number of VLBW infants with gastrointestinal dysmotility needed to be treated to prevent 1 case of PNAC is estimated to be 5 (95% CI: 2–8). This result represents a robust treatment effect. In contrast to PNAC caused by surgical-induced short gut syndrome or intestinal failure in which the infants usually have prolonged parenteral nutrition resulting in hepatic failure and death, advanced liver injury associated with gastrointestinal dysmotility of prematurity is infrequent. This observation could be confirmed by the mild to modest increase in serum alanine aminotransferase levels and the marginal significant increase in conjugated bilirubin concentrations. However, it is important to note that significantly more infants in the placebo group had abnormally raised alanine aminotransferase levels indicating a degree of hepatic damage (Table 2). Furthermore, clinical signs and biochemical parameters may sometimes be deceiving because these indicators do not necessarily correlate closely with disease severity at the late stage of deterioration, and rapid decompensation of hepatic function can occur unexpectedly after a relatively short course of parenteral nutrition. One infant in the placebo group developed life-threatening hepatic failure with markedly deranged clotting profile, portal hypertension, esophageal varices, and frank hematemesis. This infant also had multiple pathologic defects secondary to osteopenia and substrate deficiency rickets, yet he survived after tolerating full enteral feeding and cessation of hyperalimentation. To date, there is no definitive treatment for PNAC apart from stopping parenteral nutrition, and the only solution to arrest the progression of liver disease is to achieve full enteral nutrition as soon as it is practicable. Predictably, the hepatic function in all affected infants was reversible and recovered within 2–4 months after stopping parenteral nutrition.

The results also suggested that the use of oral erythromycin would significantly shorten the requirement of hyperalimentation by 10 days. This finding could be translated into substantial savings both in human resources and cost for preparation of parenteral nutrition and, more importantly, infant exposure to complications of intravenous lines such as the repeated trauma of line insertion and recurrent sepsis. The principal organisms responsible for septicemia in the current and previous studies in preterm infants were coagulase-negative staphylococci (Table 3). Because colonization of indwelling lines with these microorganisms is common after repeated infusions and bactericidal activities of phagocytosis and intracellular killing of coagulase-negative staphylococci in neutrophils are defective during long-term parenteral nutrition, shortening the need for hyperalimentation and elimination of intravascular lines could have been responsible for the significant decrease in incidence of recurrent septicemia in erythromycin-treated infants. Recurrent sepsis in the presence of PNAC could result in more rapid deterioration of hepatic function and damage of liver parenchyma by inhibiting hepatocellular bile acid transport and activation of hepatic macrophages via locally produced procholestatic cytokines such as tumor necrosis factor alpha. Thus, decreasing recurrent sepsis could have the additional benefit of interrupting the vicious cycle for causing further intrahepatic cholestasis and destruction of liver tissue.

In accordance with our previous findings, VLBW infants with functional gastrointestinal dysmotility achieved half, three-quarters, and full enteral feeding significantly earlier after treatment with high-dose oral erythromycin compared with the placebo. Nonetheless, there are controversies concerning the effectiveness of erythromycin in promoting enteral feeding. To date, of the 8 RCTs reported in the English literature, 3 used erythromycin as a prophylactic prokinetic agent and 5 as rescue treatment. Of the prophylactic studies, 2 of the 3 RCTs did not reveal any benefit, but the third study by Oei and Lui demonstrated that erythromycin-treated infants had significantly fewer episodes of large residual gastric aspirates and were able to attain full oral feeding more quickly. Prophylactic studies of such nature, however, do not necessarily reflect the efficacy of erythromycin as a prokinetic agent because infants with protracted feed intolerance are not specifically targeted for treatment. Five RCTs used erythromycin as rescue treatment in preterm newborns with feed intolerance. Two of the 5 trials, including our preliminary RCT, found erythromycin to be beneficial. Our previous study using the same high-dose (12.5 mg/kg every 6 hours for 14 days) as the current trial revealed that oral erythromycin could shorten the time for achieving full enteral nutrition and that there was a nonsignificant trend of an increased risk for developing PNAC in placebo infants. A recent study by Nuntnarumit et al also suggested that the use of an intermediate dose of oral erythromycin (10 mg/kg every 6 hours for 2 days, followed by 4 mg/kg every 6 hours for the next 5 days) could significantly reduce the number of withheld feeds and the time to full feeding. In contrast, low-dose rescue treatment (3 mg/kg administered every 6 hours intravenously, and 6–15 mg/kg/day given orally) was not useful in facilitating enteral feeding. Two of the latter trials were small, involving no more than 15 patients in each group, and, therefore, might not have adequate statistical power to detect subtle differences in feeding. In the third RCT, the infants did not have protracted feed intolerance because the mean time to attain full enteral feeding ranged between 13.6 and 16.4 days in the erythromycin and placebo groups, respectively. These investigators concluded that a larger RCT would be warranted to address this important issue. Another plausible explanation for the discrepancy of results between studies could have been related to the different dosages used. It is possible that a higher dosage (ie, an intermediate or
a high dose) is required for effective stimulation of the gastrointestinal tract.12,42

Other prokinetic agents such as cisapride and metoclopramide have been used to promote gastrointestinal motility and/or treatment of gastroesophageal reflux in infancy. However, only a small number of RCTs were performed on cisapride in preterm infants, and the number of participants involved in each study was relative small.43–48 Although 2 studies suggested that cisapride might improve feeding tolerance,43,44 others were unable to confirm such benefits.45–48 Furthermore, the latter trials demonstrated no significant advantage in reducing the daily total gastric aspirate,45,46 time to establish full enteral feeding,48 or no change and even delay in gastric emptying time45,47 or whole gut transit time.47 Additionally, serious adverse effects, including QT prolongation, life-threatening arrhythmia, and increase in thickness of the pylorus muscle, were observed.43,46,49 Even fewer data were available on metoclopramide in young infants. One case series suggested that metoclopramide might be potentially useful in infants with regurgitation or gastroparesis following abdominal surgery but not in those with gastroparesis associated with prematurity.50

Although the exact mechanism in which erythromycin facilitates advancement of enteral feeding is not fully understood, there is substantial evidence to suggest that the prokinetic action is mediated via the motilin pathway principally at the levels of the stomach and proximal small bowel.51–53 Stimulation of this pathway results in increase in the proximal gastric tone,54 greater amplitude and more frequent antral contractions,55–58 suppression of pyloric contractions and consequently reducing outlet resistance,52 and increase in the frequency of duodenal contractions.59 Recent studies have indicated the presence of 2 main types of motilin receptors.60 The neural motilin receptors on cholinergic neurons respond to low-dose (1–3 mg/kg) erythromycin and predominantly enhances the phase III migrating motor complexes, whereas the smooth muscle motilin receptors respond to higher doses of erythromycin and are mainly responsible for producing sustained antral contractions and facilitating antroduodenal coordination.30,32,53,58 Despite reports suggesting that gut immaturity could have been a crucial factor for the lack of response to erythromycin in infants <32 weeks gestation,51 the current evidence from clinical trials suggests that this could not fully explain the bedside findings.10–13 There is now evidence to suggest that the development of the gastrointestinal neuroendocrine network is mostly complete by 25 weeks gestation and that the distribution of motilin in the gastrointestinal tract at 20 weeks gestation closely resembles the pattern of distribution in adults.61,62 Thus, preterm infants at very early gestations are already equipped with the essential anatomic and physiologic apparatus necessary for proper functioning of the bowel. In addition, exposure of the immature bowel to milk or exogenous motilin can result in earlier detection of phase III motor activity than would normally be expected for the gestational age.63–65

In human studies, a case series performed in preterm infants at 23–30 weeks gestations demonstrated that the use of intravenous erythromycin (0.75 mg/kg) could significantly increase antral clusters of contractions. The antral motility index was increased 4-fold and, thus, suggested the presence of functioning motilin receptors at very early gestations.66 In another study, the same group of investigators studied different doses (10 mg vs 3 mg) of erythromycin administered orally and showed that 10 mg but not 3 mg significantly increased gastric emptying.31 It was proposed that a decrease in the pyloric tone coupled with an increase in tone of the proximal stomach could have been responsible for the prokinetic effect.31 A recent crossover study further indicated that oral erythromycin (10 mg/kg every 8 hours) enhanced antral contractility and increased whole gut transit time measured by ultrasonography and the carmine red dye method, respectively.32 In contrast, Jadhlera and Berseth using low-dose oral erythromycin (0.75–3 mg/kg) failed to initiate phase III motor migrating complexes in patients <31 weeks gestation but could induce them in a dose-dependent manner in infants ≥32 weeks.67 ElHennawy et al also reported in a RCT that low-dose oral erythromycin (1.5 mg/kg) was unable to induce stronger or more frequent antroduodenal contractions compared with untreated patients and that the transit time from duodenum to anus was similar between the 2 groups.15 Thus, the cumulating evidence suggests that the action of erythromycin for promoting enteral feeding is probably dose as well as age dependent. Because there are clinical data to support that an intermediate or a high oral dose of erythromycin10–12 is more effective than lower doses14,15 for rescue treatment, we speculate that the lower intragastric doses are probably insufficient in providing adequate drug concentrations either locally or systemically for exerting the desired prokinetic effects. The time of introduction of milk feeding 9 days (median) prior to commencement of erythromycin and the use of this prokinetic agent as rescue rather than prophylactic treatment could have the advantage of accelerating and allowing time for bowel maturation such that the gut may become more susceptible to prokinetic drug stimulation.63–65

No major adverse effect was encountered with oral erythromycin. In particular, none of the studied infants had infantile hypertrophic pyloric stenosis within the study period. The relatively low incidence of pyloric stenosis in Chinese babies68 coupled with erythromycin administration not earlier than day 13 of life29 have probably minimized the risk of developing this complication. Thus far, none of the other RCTs encountered this problem.11–18 Because the incidence of infantile hypertrophic pyloric stenosis is estimated to be 1–3 cases per 1000 live births,69 an 8-fold increase in risk because of erythromy-
cin would substantially increase the incidence to 8–24 cases per 1000 livebirths (ie, 1 case in 41- to 125-treated infants). This prevalence should have been detected by this or the combination of clinical trials. Therefore, the effect of erythromycin on infantile hypertrophic pyloric stenosis is likely to be small, and the benefits probably outweigh its risks. Three infants developed transient ventricular ectopies (Table 2). The infant in the erythromycin group developed the dysrhythmia on day 5 and before administration of prokinetic treatment, whereas the other 2 infants developed ventricular ectopies before and during placebo treatment. All patients recovered spontaneously within 12 hours of onset. No definitive cause was found. The QTc intervals before and during drug administration were similar between the 2 groups. The use of erythromycin was also not associated with an increase risk of NEC. The prevalence of NEC in the NICU has been significantly improved after introduction of new hand hygiene measures and remained at a very low level during the study period. Importantly, the stool culture surveillance showed that the pattern of microorganisms did not change significantly between erythromycin-treated and placebo infants. One culture revealed methicillin-resistant Staphylococcus aureus in a placebo infant, and the emergence of Stenotrophomonas species was associated with the use of carbapenem antibiotics in these patients (Table 4). There was no outbreak of infection and NEC or emergence of multidrug-resistant organisms within the 69-month study period.

There are limitations in this study. First, the RCT was performed in a single center, and the results may not be generalizable to other NICUs. However, the strong treatment effect suggests that the data are robust, and attending neonatologists should be able to observe similar beneficial effects in their own population. One could also argue that the majority of PNAC cases were mild and question whether an antimicrobial agent in therapeutic dose should be initiated for treatment of such a benign condition. However, a life-threatening case with hepatic failure was observed during the study period. In addition, the duration for requirement of parenteral nutrition and the incidence of recurrent septicemia were significantly decreased. The absence of any major adverse effects such as infantile hypertrophic pyloric stenosis and life-threatening cardiac arrhythmias should justify the use of oral erythromycin as a “rescue” measure for infants with moderately severe gastrointestinal dysmotility. Undoubtedly, the future development of a new generation of macrolide analogues devoid of antibiotic activity but retaining motilinomimetic properties would be a distinct advantage. Second, much effort had been focused on identifying multidrug-resistant organisms in both blood and stool cultures because the study was performed in an intensive care setting. However, these conventional microbiologic culture techniques might not be sensitive enough to detect subtle changes of microflora in the gastrointestinal tract. Recent studies suggested that the use of broad-spectrum antimicrobial agents in the early perinatal period could disturb normal developmental gene expression, impair maturation of the bowel protective barrier, interfere with the proper formation of the mucus gel layer overlying the gut epithelium, and change the pattern of microbial colonization in the gastrointestinal tract. Such modulating effects on the critical suckling-weaning transitional period could have long-lasting consequences because changes in the microbiota and gut mucosal barrier might potentially be associated with increased susceptibility to infection or developing inflammatory or atopic diseases in later life. In this aspect, microbial genomic analysis or DNA microarray analysis would be of value in future studies to identify any alteration of the bowel microbiota and long-term effects of antibiotics on the gut microenvironment.

In summary, this is the largest RCT of oral erythromycin for assessing its prokinetic effect in preterm infants and is also the first study to assess clinical outcomes systematically. Our findings suggest that the use of a rescue high-dose oral erythromycin could effectively reduce the incidence of PNAC by 50% in VLBW infants with moderately severe gastrointestinal dysmotility. In addition, the treatment is also associated with an earlier time (10.1 days) to achieve full enteral feeding, decreasing the requirement for parenteral nutrition, and reducing the number of recurrent septicemia. No major adverse effects or life-threatening complications were encountered. The findings also demonstrate the importance of using the medication appropriately in a sufficiently “high-dose” and as a “rescue” therapy. These favorable data should strengthen the confidence of neonatal clinicians in using oral erythromycin as a prokinetic agent in moderate to severe cases. Although the current evidence suggests that the use of oral erythromycin at the antimicrobial dose is probably safe and does not readily promote the emergence of multidrug-resistant organisms, the sample size may still be inadequate to detect subtle adverse effects or outcomes in the long-term. Thus, oral erythromycin in a sufficient dosage can be considered after day 14 of life as a rescue treatment in preterm infants who fail to establish adequate enteral nutrition and in whom anatomically obstructive pathologies of the gastrointestinal tract have been excluded. We, however, caution against prophylactic or routine use of erythromycin as a prokinetic agent because the data from prophylactic RCTs have not been convincing and its safety profile, especially its influence on bowel microbiota and gut protective barrier, needs to be further addressed.

References
1. Kaufman SS, Gondolesi GE, Fishbein TM. Parenteral nutrition associated liver disease. Semin Neonatal 2003:8:375–381.
2. Teitelbaum DH. Parenteral nutrition-associated cholestasis. Curr Opin Pediatr 1997;9:270–275.
3. Siu YK, Ng PC, Fung SCK, Lee CH, Wong MY, Fok TF. So KW, Cheung KL, Wong W, Cheng AFB. Double-blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 1998;79:F105–F109.

4. Bersch CL. Feeding strategies and necrotizing enterocolitis. Curr Opin Pediatr 2005;17:170–173.

5. Ng PC, Brownlee KG, Dear PRF. Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia. Arch Dis Child 1991;66:1164–1166.

6. Ng PC, Fok TF, So KW, Wong Y, Ip PK, Liu K. Lower gastrointestinal tract perforation in preterm infants treated with dexamethasone for bronchopulmonary dysplasia. Pediatr Surg Int 1997;12:211–212.

7. Stark AR, Carlo WA, Tyson JE, Papile LA, Wight LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ. National Institute of Child Health and Human Development Neonatal Research Network. Adverse effect of early dexamethasone in extremely low-birth-weight infants. N Engl J Med 2001;344:95–101.

8. Kelly DA. Liver complications of pediatric parenteral nutrition—epidemiology. Nutrition 1998;14:153–157.

9. Andorsky DJ, Lund DP, Lillevang JW, Lacanisi J, Richardson DS, Collier SB, Lo C, Duggan C. Nutritional and other post-operative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr 2001;139:27–33.

10. Ng PC, Fok TF, Lee CH, Wong W, Cheung KL. Erythromycin treatment for gastrointestinal dysmotility in preterm infants. J Pediatr Child Health 1997;33:148–150.

11. Ng PC, So KW, Fung KSC, Lee CH, Fok TF, Wong E, Wong W, Cheung KL, Cheng AFB. Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001;84:F177–F182.

12. Nutnarumit P, Kiatschoosakun P, Tantiprapa W, Boonkasidecha S. Efficacy of oral erythromycin for treatment of feeding intolerance in preterm infants. J Pediatrics 2006;93:600–606.

13. Oei J, Lui K. A placebo-controlled trial of low-dose erythromycin to promote feed tolerance in preterm infants. Acta Paediatr 2001;90:904–908.

14. Ng SC, Gomez JM, Rajadurai VS, Saw SM, Quak SH. Establishing enteral feeding in preterm infants with feeding intolerance: a randomized controlled study of low-dose erythromycin. J Pediatr Gastroenterol Nutr 2003;37:554–558.

15. ElHennawy AA, Sparks JW, Armentrout D, Huseby V, Bersch CL. Erythromycin fails to improve feeding outcome in feeding intolerant preterm infants. J Pediatr Gastroenterol Nutr 2003;37:281–286.

16. Cairns P, Craig S, Tubman R, Roberts RS, Wilson J, Schmidt B. Randomised controlled trial of low-dose erythromycin in preterm infants with feed intolerance (abstr). Pediatr Res 2002;51:379A–380A.

17. Stenson BJ, Middelmiss L, Lyon AJ. Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 1998;79:F212–F214.

18. Patole SK, Almonte R, Kadalraja R, Tuladhar R, Muller R, Whitehall JS. Can prophylactic oral erythromycin reduce time to full enteral feeds in preterm neonates? Int J Clin Pract 2000;54:504–508.

19. McLin VA, Balistreri WF. Approach to neonatal cholestasis. In: Walker WA, Gouyon JB, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647–650.

20. Andor K, Janssens J, Vantrappen G, Tack J, Peeters TL, Vlim-Erse P, Van Cutsen E. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastro-duodenal coordination. Gastroenterology 1992;102:823–828.

21. Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006;118:197–201.

22. Shek CC, Ng PC, Fung GP, Cheng FWT, Chan PK, Peiris MJ, Lee KH, Wong SF, Cheung HM, Li AM, Hon EK, Yeung CK, Chow CB, Tam JS, Chiu MC, Fok TF. Infants born to mothers with severe acute respiratory syndrome. Pediatrics 2003;112:e254–e256.

23. Farrar HC, Walsh-Sukys MC, Kylloon K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993;12:688–691.

24. Gouyon JB, Benoît A, Betremieux P, Sandre D, Sono C, Bavoil, F, Beneton C, Badoual J. Cardiac toxicity of intravenous erythromycin lactobionate in preterm infants. Pediatr Infect Dis J 1994;13:840–841.

25. Sande MA, Mandell GL. Antimicrobial agents. In: Gilman AG, Rall TW, Nies AS, eds. Goodman and Gilman’s the pharmacologic basis of therapeutics. 8th ed. Elmsford, New York: Pergamon, 1990;1130–1134.

26. Parsons RL, David JA, Raymond K, Stamp SM. Pharmacokinetics on intravenous erythromycin lactobionate. J Int Med Res 1980;8(Suppl 2):15–23.

27. Houn G, Tillement JP, Lahoste F, Rapin M, Soussy CJ, Duval J. Erythromycin pharmacokinetics in man. J Int Med Res 1980;8(Suppl 2):9–14.

28. Gouyon JB. The use of erythromycin lactobionate to facilitate the postpyloric passage of tubes in children. J Pediatr Gastroenterol Nutr 1992;14:120.

29. Cooper WO, Griffin MR, Arboag P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647–650.

30. Annesse V, Janssens J, Vantrappen G, Tack J, Peeters TL, Villemse P, Van Cutsen E. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastro-duodenal coordination. Gastroenterology 1992;102:823–828.

31. Tomomasa T, Tabata M, Nako Y, Kaneko H, Morikawa A. The effect of oral erythromycin on gastric emptying in neonates with gastric retention (abstr). Gastroenterology 1997;112(Suppl):A839.

32. Costalos C, Gounaris A, Varhalama E, Alexiou N, Kolouvou E. Erythromycin as a prokinetic agent preterm infants. J Pediatr Gastroenterol Nutr 2002;34:23–25.

33. Su BH, Lin HC, Peng CT, Tsai CH. Effect of erythromycin on feeding intolerance in very low birth weight infants: a preliminary observation. Acta Paediatr Sin 1998;39:324–326.

34. Kubota M, Nakamura T, Motokura T, Mori S, Nishida A. Erythromycin improves gastrointestinal motility in extremely low birth-weight infants. Acta Paediatr Jpn 1994;36:198–201.

35. Goldstein H. Multilevel statistical models. In: Goldstein H, ed. Kendalls library of statistics 3. London, UK: Edward Arnold, 1995:87–94.

36. Mullick FG, Moran CA, Ishak KG. Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children. Mod Pathol 1994;7:190–194.

37. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovon EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptokor AR, Stevenson DA, Papile LA, Poole WK. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285–291.

38. Okada Y, Klein NJ, van Saene HK, Webb G, Holzel H, Pierro A. Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition. Ann Surg 2000;231:276–281.
39. Reimund JM, Duclos B, Arondel Y, Baumann R. Persistent inflammation and immune activation contribute to cholestasis in patients receiving home parenteral nutrition. Nutrition 2001;17:300–304.

40. Kawaguchi T, Sakisaka S, Matsuoka Y, Handa M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatic bile ducts and increased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 2000;31:1285–1295.

41. Cui XL, Iwasa M, Kuge H, Sasaguri S, Ogoshi S. Route of feeding influences the production and expression of tumor necrosis factor α in burned rats. Surg Today 2001;31:615–625.

42. Patole S, Rao S, Doherty D. Erythromycin as a prokinetic agent in preterm neonates: a systematic review. Arch Dis Child Fetal Neonatal Ed 2005;90:F301–F306.

43. Kohl M, Wuerdemann I, Clemen J, Iven H, Katalinic A, Moeller JC. Cisapride may improve feeding tolerance of preterm infants: a randomized placebo-controlled trial. Biol Neonate 2005;88:270–275.

44. Costalos C, Gounaris A, Varhalama E, Kokori F, Alexiou N, Katsaraki I. Effect of low-dose cisapride on gastric emptying and QTc interval in preterm infants. Acta Paediatr 2000;89:1446–1448.

45. Barnett CP, Omari T, Davidson GP, Goodchild L, Dent J, Haslam RR. Effect of cisapride on gastric emptying in premature infants with feed intolerance. J Paediatr Child Health 2001;37:559–563.

46. Pezzati M, Dani C, Biaiaoli R, Gambi B, Lachina L, Rubaltelli FF. Randomised controlled trial of the effect of cisapride on the pyloric muscle in preterm infants. Eur J Paediatr 2001;160:572–575.

47. McClure RJ, Kristensen JH, Grauaug A. Randomised controlled trial of cisapride in preterm infants. Arch Dis Child Fetal Neonatal Ed 1999;80:F174–F177.

48. Enriquez A, Bolisetty S, Patoles S, Garvey PA, Campbell PJ. Randomised controlled trial of cisapride in feed intolerance in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998;79:F110–F113.

49. Corvaglia L, Faldella G, Rotatori R, Lanari M, Capretti MG, Salvioli GP. Intraluminal growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants. Cardiovasc Drugs Ther 2004;18:371–375.

50. Hyman PE, Abrams CE, Dubois A. Gastric emptying in infants: response to metoclopramide depends on the underlying condition. J Pediatr Gastroenterol Nutr 1988;7:181–184.

51. Jadhcherla SR, Klee G, Berseth CL. Regulation of migrating motor complexes by motilin and pancreatic polypeptide in human infants. Pediatr Res 1997;42:365–369.

52. Mathis C, Malbert CH. Changes in pyloric resistance induced by erythromycin. Neurogastroenterol Motil 1998;10:131–138.

53. Caille B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998;43:395–400.

54. Varannes SBD, Parys V, Ropert A, Chavyaille JA, Roze C, Galmiche JP. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995;109:32–39.

55. Janssens J, Peeters T, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990;322:1028–1031.

56. Holle GE, Steinbach E, Forth W. Effects of erythromycin in the dog upper gastrointestinal tract. Am J Physiol 1992;263:G52–G59.

57. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol 1990;259:G355–G363.

58. Tack J, Janssens J, Vantrappen G, Peeters T, Annese V, Depoortere I, Muls E, Bouillon R. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992;103:72–79.

59. Fraser R, Shearer T, Fuller J, Horowitz M, Dent J. Intravenous erythromycin overcomes small intestinal feedback on antral, pyloric, and duodenal motility. Gastroenterology 1992;103:114–119.

60. Parkman HP, Pagano AP, Vozzelli MA, Ryan JP. Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. Am J Physiol 1995;269:G418–G426.

61. Bisset WM, Watt JB, Rivers RPA, Mill PJ. Ontogeny of fasting small intestinal motor activity in the human infant. Gut 1988;29:483–488.

62. Berseth CL. Gestational evolution of small intestinal motility in preterm and term infants. J Pediatr 1989;115:646–651.

63. Vantrappen GR, Janssens J, Peeters TL, Bloom SR, Christofides ND, Hellemans J. Motilin and the interdigestive motor complex in normal and preterm infants. Pediatr Res 1997;42:497–500.

64. Janssens J, Hellemans J, Adrian TE, Bloom SR, Peeters TL, Christofides N, Vantrappen GR. Pancreatic polypeptide is not involved in the regulation of the migrating motor complex in man. Regul Pept 1982;3:41–49.

65. Berseth CL, Nordyke C. Enteral nutrients promote postnatal maturation of intestinal motor activity. Am J Physiol 1993;264:G1046–G1051.

66. Tomomasa T, Miyaizaki M, Koizumi T, Kurotome T. Erythromycin increases gastric antral motility in human premature infants. Biol Neonate 1993;63:349–352.

67. Jadhcherla SR, Berseth CL. Effect of erythromycin on gastroduodenal contractile activity in developing neonates. J Pediatr Gastroenterol Nutr 2002;34:16–22.

68. Ng PC, Fok TF, Nelson EAS. Neonatologist in the “Pearl of the East.” J Paediatr Child Health 1996;32:362–367.

69. Sørensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schanheyder HC. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003;35:104–106.

70. Ng PC, Wong HL, Lyon DJ, So KW, Liu F, Lam RK, Wong E, Cheng AF, Fok TF. Combined use of alcohol hand rub and gloves reduces the incidence of late onset infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2004;89:F336–F340.

71. Verhagen MAMT, Samsom M, Maes B, Geypens BJ, Ghoos YF, Smout AJ. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997;11:1077–1086.

72. Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A, Visser MR, Verhoef J, Goossen HG, Ackermans LM. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999;29:33–40.

73. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004;5:569–573.

74. Schumann A, Nutten S, Donnicola D, Comelli EM, Mansourian R, Cherbut C, Corthesy-Theulaz I, Garcia-Rodenas C. Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. Physiol Genomics 2005;23:235–245.
tai, Shatin, N.T., Hong Kong. e-mail: pakcheungng@cuhk.edu.hk; fax: (852) 2636 0020.

Supported for phase 1 of the randomized controlled study by the Department of Pediatrics, Chinese University of Hong Kong, and, for phase 2 of the study, by research grants awarded by the Research Grant Council of the Government of Hong Kong SAR (Project code: 4163/02M) and by the H. M. Lui Memorial Fund (Project code: 6901814).

Competing interest statement: None of the authors have any conflicts of interest to disclose.